For three years every weight-loss headline has run through one mechanism: GLP-1. A small Brazilian-led trial just put a different molecule on the board. A 10-amino-acid peptide called Pep19, dosed once a night for 60 days, cut visceral fat by 17% in obese adults and improved their sleep — without acting on GLP-1, GIP, or glucagon at all.
Pep19 is now sold to consumers as the supplement Nutroslim, which is why search interest is climbing faster than the evidence behind it. Here is exactly what the trial showed, how the mechanism works, and where it sits relative to the peptides that actually have a deep evidence base.
Research-context information only. Pep19 is a research peptide sold as a dietary supplement. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Pep19 Is
Pep19 is a synthetic 10-residue peptide with the sequence DIIADDEPLT, derived from a fragment of cyclophilin A and produced by standard FMOC solid-phase synthesis. Mechanistically it acts as a weak inverse agonist at the cannabinoid type 1 (CB1) receptor — the same receptor system that, when overactive, drives appetite, lipid storage, and metabolic dysfunction.
That target has history. The CB1 antagonist rimonabant reached the market in Europe as a weight-loss drug before being pulled in 2008 over psychiatric side effects, because it crossed into the brain and blunted CB1 signaling centrally. Pep19's pitch is that it acts as a weak peripheral modulator rather than a strong central blocker, which the researchers argue is why the trial reported no central nervous system adverse effects. Preclinical work also reported that Pep19 activates UCP1 and pushes white adipose tissue toward a brown-fat phenotype — a thermogenic, fat-burning state.
The 60-Day Trial
The study published in Diabetes/Metabolism Research and Reviews (Heimann et al., 2025; PMID 40450548) was a triple-blind, placebo-controlled trial of 24 obese adults aged 46–59 with a BMI between 30 and 35. Participants took 2 mg or 5 mg of Pep19, or placebo, once daily at bedtime for 60 days.
Reported Results
| Outcome | 5 mg arm | 2 mg arm |
|---|---|---|
| Visceral fat | −17% (± 4.7%) | not significant |
| Sleep quality | improved | +35% (± 10%) |
| Lean mass | no change | no change |
| Adverse effects | none reported | none reported |
The visceral-fat reduction in the 5 mg arm reached statistical significance (p < 0.05) with no loss of lean tissue, and body weight and waist circumference fell significantly in that group as well. Sleep quality improved in both active arms — notably, the lower 2 mg dose produced the larger sleep effect, which the authors tie to CB1's role in the sleep-wake cycle. The trial reported no adverse events in either dose group.
How to Read a 24-Person Result
The honest framing matters here, because the gap between what the headline says and what the data supports is wide.
This is a 24-person, 60-day, early-stage trial. Visceral fat specifically — the deep abdominal fat tied to metabolic and cardiovascular risk — moving 17% without lean-mass loss is a genuinely interesting signal, and the dual visceral-fat-plus-sleep effect is unusual. But a single small trial from one research group is a hypothesis generator, not a verdict. The effect needs replication in larger, longer, independently run studies before it means much for anyone's decision.
For perspective: the obesity drugs with regulatory approval ran trials enrolling hundreds to thousands of patients across 48–80 weeks. Pep19 has 24 people and two months. Treat the two as living on entirely different evidence tiers.
What This Means If You're Comparing Fat-Loss Peptides
Pep19 is now sold as a consumer supplement (Nutroslim), but it is not stocked by research-peptide vendors and has no FDA-approved counterpart. If you arrived here comparing peptides for fat loss or visceral-fat reduction, the practical landscape looks like this:
- The deep evidence base is still GLP-1-class. Semaglutide (~15% mean weight loss in Phase 3), tirzepatide (~22.5%), and the triple agonist retatrutide (up to ~30% in TRIUMPH-1) are where the large, replicated human data sits.
- The closest non-GLP-1 option available from research vendors today is cagrilintide, an amylin analog stocked widely. It targets satiety through a different pathway than GLP-1, much as Pep19 does, but with substantially more clinical data behind it. See the cagrilintide vendor comparison.
- Pep19/Nutroslim itself remains a single-trial supplement. There is no COA-verified research-grade supply chain for it the way there is for established peptides, and no independent purity or potency testing standard in the consumer-supplement form.
For current pricing and active discount codes across the obesity-peptide category, see the /deals page.
